Clinical trials: Prostate Cancer Metastatic
Prostatic Neoplasms, Neoplasm Metastasis
Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery.
- Trial name
- NCT04790968
- Testing
- PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with…
- Trial name
- AFFINITY (NCT01578655)
- Testing
- cabazitaxel, prednisone, custirsen sodium
- Where
- 94 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Achieve Life Sciences
Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that…
- Trial name
- NCT00038194
- Testing
- imatinib mesylate, docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting
The purpose of this study is to investigate the prevalence of tissue homologous recombination repair (HRR)-related gene mutations (positive/negative/Variant of uncertain significance (VUS)), clinical outcome such as…
- Trial name
- ZENSHIN (NCT04425200)
- Where
- 26 sites in Japan
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Castration-resistant Prostate Cancer
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with…
- Trial name
- RAPIT (NCT04232761)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Bayer
Breast Cancer, Non Small Cell Lung Cancer
Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer
- Trial name
- NCT00278070
- Testing
- vinorelbine oral formulation
- Where
- 11 sites in Greece
- Sponsor
- Hellenic Cooperative Oncology Group
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT02803437
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223)
- Where
- Japan
- Volunteers
- 334 people
- Sponsor
- Bayer
Prostate Cancer
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC.
- Trial name
- NCT02262910
- Testing
- ES414
- Where
- 7 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Aptevo Therapeutics
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy
This trial studies image-guided biopsies work in identifying mechanisms of resistance in participants with castration resistant prostate cancer that has spread to other places in the body and who are undergoing radioligand…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03596710
- Testing
- Image Guided Biopsy
- Sponsor
- Jonsson Comprehensive Cancer Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Neoplasm, Prostate
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer
Objectives I. Compare, in a randomized Phase III multi-institutional setting, symptom-free survival time of patients with asymptomatic carcinoma of the prostate (T0-4, N0-2, M0) not suited for local curative treatment who are…
- Trial name
- NCT01819285
- Testing
- Immediate Orchiectomy or depot LHRH, Delayed Orchiectomy or depot LHRH
- Volunteers
- 985 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer.
- Trial name
- PROPET (NCT00670527)
- Testing
- [18F] Fluorocholine PET/CT
- Where
- Denmark
- Volunteers
- 205 people
- Sponsor
- Odense University Hospital
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Blood for Immune Response to Provenge® in HRPC
This study is being conducted to assess and monitor immune response in patients with minimally symptomatic or asymptomatic hormone refractory prostate cancer who will be receiving Provenge® (Sipuleucel-T) therapy as part of their…
- Trial name
- NCT01274572
- Sponsor
- Mary Crowley Medical Research Center
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Castration Resistant Prostate Cancer
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined…
- Trial name
- PREMISE (NCT02495974)
- Testing
- enzalutamide
- Where
- 182 sites in Austria, Belgium and 14 more
- Volunteers
- 1,763 people
- Sponsor
- Astellas Pharma Europe Ltd.
Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate…
- Trial name
- NCT07428642
- Testing
- Androgen Deprivation Therapy, Apalutamide, Enzalutamide
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate…
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02012296
- Testing
- enzalutamide, mifepristone, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- University of Chicago